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ORIGINAL ARTICLE
Background/Aims: Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration. The
aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes
after stent implantation in patients with coronary artery disease. 
Methods: We performed a prospective trial with male subjects to compare the safety and effects of carvedilol-
loaded BiodivYsio
® stents implanted into 20 patients with those of bare-metal BiodivYsio
® stents implanted into
21 patients for de novo coronary lesions. The primary end point was the degree of neointimal hyperplasia, which
was measured by intravascular ultrasound (IVUS) 6 months after the procedure; the secondary end point was
major adverse cardiac events (MACE) at 2 years after implantation. All carvedilol and control stents were
deployed successfully. 
Results: A 2-year follow-up was completed for 19 patients (95%) in the carvedilol stent group and 20 patients
(95%) in the control stent group. IVUS showed a trend toward a larger luminal area (6.86 ± 2.59 vs. 5.47 ± 1.52
mm
2, p = 0.267), smaller neointimal area (1.34 ± 0.70 vs. 2.40 ± 1.73 mm
2, p = 0.18), and reduced net decrease
in luminal area (-0.78 ± 0.97 vs. -1.89 ± 1.78 mm
2, p = 0.106) in the carvedilol stent group compared with the
control stent group, respectively. There were no significant differences in the incidence of MACE (10.5 vs.
30.0%, respectively, p = 0.132) between the groups at 2 years after stent implantation. Stent thrombosis did not
occur in either group after 2 years.
Conclusions: The carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of
cardiac death, myocardial infarction, or stent thrombosis at 2-year follow-up. (Korean J Intern Med 2011;26:41-
46)
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INTRODUCTION
The long-term clinical efficacy of intracoronary stenting
is mainly limited by restenosis due to neointimal hyper-pla-
sia, which is caused by inflammation in the vessel wall in
response to arterial injury after stent implantation, as well
as cytokine- and growth factor-induced smooth muscle
migration, proliferation, and proteoglycan deposition [1-3].
Carvedilol is a non-selective β-adrenergic antagonist and
vasodilator with antioxidative and free-radical-scavenging
properties [4]. It also inhibits vascular smooth muscle cell
proliferation, migration, and extracellular matrix synthesis
[5-7]. Carvedilol, therefore, is expected to reduce neointimal
hyperplasia, and we previously showed that carvedilol-
loaded stents were effective in the prevention of coronary
restenosis in a porcine model [8]. However, no humanstudy has been undertaken to prove their efficacy.
We hypothesized that the delivery of carvedilol by a stent
can prevent neointimal hyperplasia and improve long-term
clinical outcomes in patients with coronary artery disease.
In this study, we investigated the beneficial effects of
carvedilol-loaded stents based on 2-year clinical outcomes
after stent implantation. 
METHODS
Study population
We performed a prospective trial using male subjects to
compare the safety and effects of carvedilol-loaded
BiodivYsio
® stents (Biocompatibles Ltd., Farnham, UK)
which were implanted into 20 patients, with those of bare-
metal BiodivYsio
® stents, which were implanted into 21
patients for de novo coronary lesions between November
2003 and September 2005 at Chonnam National University
Hospital. The inclusion criteria were aged between 18 and
80 years, reference diameter between 2.5 and 4.0 mm,
lesion length < 25 mm, and critical stenosis (> 70%) on
angiography. Patients with graft-vessel stenosis, cardio-
genic shock, a left ventricular ejection fraction < 35%, or
contraindications for antiplatelet agents were excluded
from the study. The study protocol was reviewed and
approved in sequence by the Ministry of Health and
Welfare and the Ethics Committee of Chonnam National
University Hospital. Informed consent was obtained from
all patients.
Stent preparation 
Carvedilol (Boehringer, Mannheim, Germany) was
loaded onto 3.0 × 15 mm BiodivYsio
® drug-delivery stents
(Biocompatibles Ltd.) at a concentration of 5 mg/mL,
which was prepared by dissolving powdered carvedilol in
methanol. Each stent was immersed in the drug solution
for 5 minutes, then removed from the solution and air-
dried. The amount of drug loaded onto the stents was
measured by high-performance liquid chromatography
(HPLC). The stents were kept in individual vials contain-
ing HPLC mobile phase solvent (acetonitrile [60%] and
0.25 mol/L ammonium acetate [40%]) then placed in an
ultrasound bath for a 30-minutes extraction. We previ-
ously showed that about 50% of the loaded carvedilol was
released after 5 minutes, 77% after 30 minutes, and 85%
after 60 minutes based on in vitro release kinetics [8].
Study procedure and definition
All procedures were done according to standard techni-
ques: randomly selected stents were deployed after predi-
lation with a balloon catheter. Additional balloon dilata-
tion was performed in cases of remaining residual steno-
sis. All patients received aspirin (300 mg at least 12 hours
before stent implantation and 100-200 mg/day indefinite-
ly), ticlopidine (500 mg at least 6 hours before stent
implantation and 250 mg/day for two months), or clopi-
dogrel (300 mg at least 6 hours before stent implantation
and 75 mg/day for two months). Unfractionated heparin
was administered as a 5,000 U bolus, followed by 1,000
U/hour and an additional 5,000 U just before percuta-
neous coronary intervention (PCI) to maintain the activat-
ed clotting time at 250-300 seconds.
Coronary angiography was performed at baseline.
Quantitative measurements of the diameter of the coro-
nary arteries were obtained by a blinded reviewer using a
workstation with dedicated software (Phillips H5000 or
Allura DCI). From two orthogonal views, the minimal
lumen diameter and interpolated reference diameter were
calculated as a mean. All intravascular ultrasound (IVUS)
studies were performed at the time of the procedure and 6
months after the procedure by a follow-up angiogram.
The images were acquired with motorized pullback at a
constant speed of 1 mm/sec (Galaxy, Boston Scientific,
Natick, MA, USA). Using volumetric analysis, we mea-
sured the external elastic membrane (EEM) and lumen
cross-sectional area (CSA). The plaque plus media (P&M)
CSA was calculated as the EEM CSA minus the lumen CSA,
and the plaque burden was calcul-ated as the P&M CSA
divided by the EEM CSA. The lesion was the site with the
smallest lumen CSA. In cases where multiple image slices
had the same minimum lumen CSA, the image slice with
the largest EEM and P&M was measured. 
A successful procedure was defined as a patient-treated
vessel with anterograde thrombolysis in myocardial
infarction flow-grade III and angiographic residual steno-
sis < 20% without the occurrence of any cardiac events.
In-stent restenosis was defined as in-stent luminal diame-
ter stenosis > 50%; stent thrombosis was defined accord-
ing to academic research consortium criteria [9].
Study endpoints
The primary end point was the degree of neointimal
hyperplasia, which was measured by IVUS at 6 months
after the procedure; the secondary end point was major
adverse cardiac events (MACE; cardiac death, non-fatal
42 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011myocardial infarction, and percutaneous or surgical target
vessel revascularization) at the 2-year clinical follow-up. 
Statistical analysis 
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA), was
used for all analyses. Continuous variables are presented
as the mean value ± SD; comparisons were conducted by
Student's t test, or by a nonparametric Wilcoxon test if the
normality assumption was violated. Discrete variables were
presented as percentages and relative frequencies; com-
parisons were conducted by χ
2 statistics or Fisher’s exact
test as appropriate. A p value < 0.05 was considered sta-
tistically significant.  
RESULTS
Baseline and procedural characteristics
No significant differences were noted in terms of age,
sex, risk factors for coronary artery disease, clinical present-
ation, creatinine clearance level as calculated by the
Cockcroft-Gault equation, and left ventricular ejection
fraction between the groups (Table 1). 
The two groups showed no significant difference in the
target vessels, the number of diseased vessels, or ACC/
AHA lesion type. All carvedilol and control stents were
deployed successfully. No significant differences in stent
length and diameter were found between the groups
(Table 2). No significant complications were detected after
the procedure in either group.
IVUS results
No significant differences in the baseline pre- and post-
PCI IVUS findings were observed between the groups.
Follow-up IVUS showed a trend toward a smaller neointimal
area and larger luminal area in the carvedilol-loaded stent
group compared with the control stent group. Moreover,
there was a trend toward a reduced net decrease in
intrastent luminal area in the carvedilol-loaded stent
group compared with the control stent group (Table 3).
Clinical follow-up results
A 2-year follow-up was completed for 19 patients (95%)
in the carvedilol-loaded stent group and 20 patients (95%)
in the control stent group. No significant differences in the
incidence of total MACE (10.5 vs. 30.0%, respectively, p =
0.13), cardiac death (0% in both groups), nonfatal
myocardial infarction (0% in both groups), target lesion
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Table 1. Baseline clinical characteristics
Characteristics Carvedilol stent  Control stent p value
(n = 19) (n = 20)
Age, yr 57.2 ± 10.4 60.2 ± 8.4 0.328
Female 4 (21.1) 4 (20.0) 0.935
Risk factor
Diabetes mellitus  3 (15.8) 4 (20.0) 0.732
Hypertension  7 (36.8) 8 (40.0) 0.839
Dyslipidemia  7 (36.8) 4 (20.0) 0.243
Current smoker  9 (47.4) 4 (20.0) 0.074
Family history  2 (10.5) 1 (5.0) 0.517
Clinical presentation 0.488
Stable angina 2 (10.5) 3 (15.0)
Unstable angina 13 (68.4) 15 (75.0)
NSTEMI 2 (10.5) 2 (10.0)
STEMI 1 (5.3) 0 (0.0)
Previous PCI 1 (5.3) 2 (10. 0) 0.579
Previous MI 1 (5.3) 1 (5.0) 0.970
Creatinine clearance, mL/min 81.62 ± 13.84 82.45 ± 19.62 0.882
Ejection fraction, % 66.9 ± 6.3 69.0 ± 6.9 0.342
Values are presented as number (%) or mean ± SD.
NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; PCI, percutaneous
coronary intervention; MI, myocardial infarction.44 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
Table 3. Intravascular ultrasound results
Carvedilol stent  Control stent p value
(n = 19) (n = 20)
Preintervention
Proximal reference EEM CSA, mm
2 14.8 ± 2.28 15.9 ± 5.26 0.542
Lesion site EEM CSA, mm
2 14.7 ± 3.25 13.8 ± 3.75 0.616
Lesion site luminal area, mm
2 4.27 ± 1.22 5.67 ± 3.24 0.251
Lesion site plaque + media CSA, mm
2 10.9 ± 2.83 8.62 ± 3.36 0.131
Lesion site plaque burden, % 70.2 ± 8.19 58.4 ± 21.2 0.120
Distal reference EEM CSA, mm
2 11.5 ± 3.21 19.2 ± 18.2 0.206
Postintervention stent CSA 8.30 ± 2.05 8.21 ± 1.79 0.922
Follow-up
Proximal reference EEM CSA, mm
2 14.7 ± 2.15 15.2 ± 3.96 0.685
Stent CSA 8.26 ± 2.15 7.87 ± 1.59 0.724
Intrastent luminal area, mm
2 6.86 ± 2.59 5.47 ± 1.52 0.267
Intrastent NIH area, mm
2 1.34 ± 0.70 2.40 ± 1.73 0.181
Distal reference EEM CSA, mm
2 11.6 ± 3.37 13.0 ± 4.51 0.438
Serial comparison between preintervention and follow-up, mm
2
∆ proximal reference EEM CSA  -0.17 ± 0.23 -0.22 ± 0.19 0.592
∆ stent CSA  -0.08 ± 0.23 -0.02 ± 0.23 0.598
∆ intrastent luminal area   -0.78 ± 0.97 -1.89 ± 1.78 0.106
∆ distal reference EEM CSA   -0.27 ± 0.51 -0.53 ± 0.94 0.453
Values are presented as mean ± SD.
EEM, external elastic membrane; CSA, cross-sectional area; NIH, neointimal hyperplasia.
Table 2. Coronary angiographic characteristics
Characteristics Carvedilol stent  Control stent p value
(n = 19) (n = 20)
Baseline angiographic finding
Target vessel  0.733
Left anterior descending artery 11 (57.9) 14 (70.0)
Left circumflex artery 4 (21.1) 3 (15.0)
Right coronary artery 4 (21.1) 3 (15.0)
Diseased vessel number  0.622
One 15 (78.9) 17 (85.0)
Two 4 (21.1) 3 (15.0)
ACC/AHA classification  0.367
Type A 0 (0.0) 1 (5.0)
Type B1 17 (94.4) 19 (95.0)
Type B2 1 (5.6) 0 (0.0)
Reference vessel diameter, mm 3.08 ± 0.34 3.09 ± 0.48 0.929
Pre-procedural MLD, mm 1.04 ± 0.42 1.39 ± 0.50 0.116
Lesion length, mm 10.7 ± 3.26 9.12 ± 3.81 0.357
Post-procedural finding
Post-procedural MLD, mm 2.87 ± 0.30 2.85 ± 0.49 0.906
Values are presented as number (%) or mean ± SD.
ACC/AHA, American College of Cardiology/American Heart Association; MLD, minimal lumen diameter.revascularization (10.5 vs. 25.0%, p = 0.24), and target
vessel revascularization (10.5 vs. 30.0%, p = 0.13) between
groups were found. Neither group showed stent thrombo-
sis at the 2-year follow-up (Table 4).
DISCUSSION
This study is the first randomized, prospective clinical
trial to evaluate the effects of carvedilol-loaded stents in
patients with coronary artery disease in terms of their
long-term clinical outcomes. Patients who received car-
vedilol-loaded stents were free of procedure-related com-
plications and acute, subacute, late, and very late stent
thrombosis.
Although the incidence of MACE was not significantly
different between the two groups, the target vessel revas-
cularization rate was almost three times higher in the con-
trol bare-metal stent group compared with the carvedilol
stent group. Additionally, a tendency toward decreased
neointimal hyperplasia in serial IVUS measure-ments was
observed in the carvedilol stent group despite a larger
plaque burden before stenting. The carvedilol-loaded
stents, therefore, were expected to have a potential thera-
peutic benefit for the prevention of in-stent restenosis.
Recent advances in drug-eluting stents have markedly
reduced the incidence of in-stent restenosis [10,11].
However, no improvement in terms of long-term prog-
nosis [12] has occurred, possibly due to late or very late
stent thrombosis [13]. Re-endothelialization and the inhi-
bition of wound healing by paclitaxel and sirolimus have
been suggested as a biologic mechanism of late stent
thrombosis [14,15]. At the 2-year follow-up, late or very
late stent thrombosis was absent in the carvedilol-loaded
stent group. In our previous porcine study [8], pathologic
examination at 28 days after stent implantation revealed
complete and equivalent healing and re-endothelialization
in the control, probucol, and carvedilol-loaded stent groups.
In addition, pharmacological studies have revealed that
carvedilol may protect the ischemic myocardium and offer
vascular protection against other chronic pathological
processes, including atherosclerosis and acute vascular
injuries arising from coronary artery procedures due to its
antioxidative and anti-inflammatory properties [16].
Nevertheless, it is unknown whether carvedilol itself pro-
motes re-endothelialization, similar to probucol [17].
The main limitations of this study are the small number
of patients and the fact that it was a single-center study.
Specifically, our study included only 41 patients with de
novo, single-vessel, relatively simple lesions. Considering
the small number of patients used to assess the clinical
outcomes, a large-population study is needed to evaluate
the safety and efficacy of carvedilol-loaded stents.
In conclusion, the carvedilol-loaded stents used in this
study tended to inhibit neointimal hyperplasia without the
occurrence of cardiac death, myocardial infarction, and
stent thrombosis. These observations require confirma-
tion in a large, randomized, multicenter study.
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Table 4. Clinical outcomes at 2-year follow-up after stent implantation
Carvedilol stent  Control stent p value
(n = 19) (n = 20)
Total MACE
Cardiac death 0 (0.0) 0 (0.0) 1.00
Nonfatal MI 0 (0.0) 0 (0.0) 1.00  
TLR 2 (10.5) 5 (25.0) 0.239
TVR 2 (10.5) 6 (30.0) 0.132
CABG 0 (0.0) 0 (0.0) 1.00
Values are presented as number (%).
MACE, major adverse cardiac events; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revasculariza-
tion; CABG, coronary artery bypass graft.Acknowledgements
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